Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

739.70INR
1:50pm IST
Change (% chg)

Rs7.80 (+1.07%)
Prev Close
Rs731.90
Open
Rs736.00
Day's High
Rs747.50
Day's Low
Rs728.90
Volume
1,351,093
Avg. Vol
1,468,098
52-wk High
Rs747.50
52-wk Low
Rs367.50

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin... (more)

Overall

Beta: 0.51
Market Cap(Mil.): Rs575,682.50
Shares Outstanding(Mil.): 802.96
Dividend: 2.00
Yield (%): 0.28

Financials

  CIPL.NS Industry Sector
P/E (TTM): 48.80 39.43 40.59
EPS (TTM): 14.69 -- --
ROI: -- 16.96 16.27
ROE: -- 17.47 17.23
Search Stocks

BUZZ-India's pharma shares gain on foreign buying, mgmt commentary

** Lupin gains 3.5 pct, Glenmark Pharmaceuticals is up 2.3 pct, while Cipla surges 5 pct

13 Feb 2015

BRIEF-India's Cipla agrees to buy 60 pct stake in Jay Precision for $15 mln

* Says agrees to buy 60 percent stake in Jay Precision Pharmaceuticals Pvt Ltd for 960 million rupees ($15.44 million) in cash

12 Feb 2015

Cipla Q3 net profit up 15.5 pct

MUMBAI - Cipla Ltd, India's fourth-largest drugmaker by sales, on Thursday reported a 15.5 percent rise in its third-quarter profit, slightly lagging analysts' estimates.

12 Feb 2015

India's Cipla Q3 net profit up 15.5 pct

MUMBAI, Feb 12 - Cipla Ltd, India's fourth-largest drugmaker by sales, on Thursday reported a 15.5 percent rise in its third-quarter profit, slightly lagging analysts' estimates.

12 Feb 2015

BUZZ-India's Cipla surges to record high on generic Nexium supply hopes

** India's Cipla rises as much as 4.8 pct to record high of 710 rupees

27 Jan 2015

Delhi High Court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI - The Delhi High Court has barred generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

India court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI - An Indian court has barred Indian generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

UPDATE 1-India court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI, Jan 13 - An Indian court has barred Indian generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

India court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI, Jan 13 - An Indian court has barred Indian generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

Aspen, Cipla win share of $860 million South Africa AIDS drug tender

JOHANNESBURG - South Africa will spend 10 billion rand ($860 million) between 2015 and 2017 on life-prolonging HIV/AIDS treatment drugs, health authorities said on Wednesday, as studies show the prevalence of the virus is rising.

24 Dec 2014

Earnings vs. Estimates

Search Stocks